US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

239.49

+3.101.31%

Pre-market: 239.49-0.00180.00%04:56 EDT

Volume:28.69K

Turnover:6.84M

Market Cap:475.75M

PE:- -

High:239.49

Open:236.45

Low:236.45

Close:236.40

52wk High:244.35

52wk Low:160.91

Shares:1.99M

Float Shares:1.99M

Volume Ratio:3.93

T/O Rate:1.44%

Dividend:0.95

Dividend Rate:0.39%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live

Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BBH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":239.4918,"timestamp":1788292800000,"preClose":236.396,"halted":0,"volume":28687,"hourTrading":{"tag":"盘前","latestPrice":239.49,"preClose":239.4918,"latestTime":"04:56 EDT","volume":1,"amount":239.49,"timestamp":1788339417440,"change":-0.0018,"changeRate":-0.000008,"amplitude":0},"delay":0,"changeRate":0.013095822264336223,"floatShares":1986503,"shares":1986503,"eps":0,"marketStatus":"Pre-Mkt","change":3.0958,"latestTime":"09-02 07:41:21 EDT","open":236.45,"high":239.4918,"low":236.45,"amount":6840002,"amplitude":0.012867,"askPrice":380.79,"askSize":100,"bidPrice":220,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788355800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":239.4918,"sharesOutstanding":1976503,"nav":236.27832,"aum":469367592.63,"dividendRate":0.00395,"bidAskSpread":0.001117,"preHourTrading":{"tag":"盘前","latestPrice":239.49,"preClose":239.4918,"latestTime":"04:56 EDT","volume":1,"amount":239.49,"timestamp":1788339417440,"change":-0.0018,"changeRate":-0.000008,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":239.0965,"preClose":239.4918,"latestTime":"16:23 EDT","volume":18,"amount":4311.9544,"timestamp":1788294232639,"change":-0.3953,"changeRate":-0.001651,"amplitude":0},"volumeRatio":3.9283269779597743,"impliedVol":0.1997,"impliedVolPercentile":0.6056},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":1986503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.9283269779597743,"shares":1986503,"dividePrice":0.9459,"high":239.4918,"amplitude":0.012867,"preClose":236.396,"low":236.45,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":239.4918,"committee":-0.980198,"eps":0,"divideRate":0.00395,"volume":28687,"delay":0,"ttmEps":0,"open":236.45,"prevYearClose":189.2649,"prevWeekClose":236.4764,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":243.7264,"twentyDayClose":208.0336,"sixtyDayClose":187.9971},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1145744656","title":"US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1145744656","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145744656?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:24","pubTimestamp":1787912643,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has officially approved Revolution Medicines' self-developed pancreatic cancer treatment, Rasonque, this week. This approval represents a significant triumph for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IDNA","LABU","IE00BJT1NW94.SGD","BK4585","IE0002141913.USD","BK4139","CANC","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4588","LU0320765992.SGD","PTH","IE00BJJMRZ35.SGD","RVMD","IE00B4R5TH58.HKD","BBH","IE0009354923.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762030","title":"Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762030","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662762030?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:17","pubTimestamp":1787883449,"startTime":"0","endTime":"0","summary":"Gilead breaks ground on Foster City biologics facility in $32 billion US investment pushGilead broke ground on its Chess biologics facility at its Foster City, California headquarters as part of a pla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL98vB5b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948897.HKD","IE0002270589.USD","LU0859254822.USD","LU0965508806.USD","LU0965509101.SGD","BMED","GILD","IBB","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU1674673428.USD","LU1066053197.SGD","BIB","LU0234570918.USD","SG9999015952.SGD","LU1061106388.HKD","LU0109394709.USD","IE00B19Z3581.USD","BK4578","LU1430594728.SGD","LU1066051498.USD","LU1037948541.HKD","BK4568","LU0289739699.SGD","BBH","LU0861579265.USD","IBBQ","LU2357627491.SGD","LU2468319806.SGD","LU0058720904.USD","BK4532","LU0320765992.SGD","LU0823416689.USD","LU0965509283.SGD","IE00BSNM7G36.USD","LU2324357040.USD","LU1571399168.USD","LU0889565916.HKD","BK4583","TBXU","LU1934455194.USD","LU1674673691.USD","TMED","LU1057294990.SGD","LU2087621335.USD","MEDI","LU0965509010.AUD","LU2112291526.USD","LU1934455863.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037671","title":"Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662037671?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:21","pubTimestamp":1787880060,"startTime":"0","endTime":"0","summary":"Earlier this year, an oncology biotech with no drugs on the market-just promising research-was attracting takeover interest. Revolution Medicines stayed independent.This week, that bet paid off.The 12","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","PTH","IE00B2B36J28.USD","LU0320765992.SGD","BK4139","IE00B4R5TH58.HKD","IE0002141913.USD","CANC","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","RVMD","LU0889565916.HKD","IDNA","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662394370","title":"Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662394370","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662394370?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:45","pubTimestamp":1787870729,"startTime":"0","endTime":"0","summary":"Gilead Sciences director Anthony Welters disposes of USD 2.64 million in common sharesGilead director Anthony Welters exercised stock options for 18,000 shares on Aug. 26, 2026 at prices of USD 60.67 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL29Bbzm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0889565916.HKD","LU0122379950.USD","GILD","BK4583","LU1571399168.USD","LU1037948897.HKD","MEDI","BK4588","TBXU","LU1057294990.SGD","LU0965509101.SGD","IE00BSNM7G36.USD","BIB","LU0289739699.SGD","IE00B3T34201.USD","LU0109394709.USD","LU1061106388.HKD","BK4578","IE00B19Z3B42.SGD","BK4139","BK4585","LU1066051498.USD","LU1934455863.HKD","LU1023059063.AUD","BK4568","LU0965508806.USD","LU1430594728.SGD","LU2324357040.USD","IBB","LU0058720904.USD","TMED","IBBQ","IE00B7SZLL34.SGD","LU0965509010.AUD","LU2087621335.USD","LU0861579265.USD","BK4566","IE0002270589.USD","LU0859254822.USD","LU1674673428.USD","LU1839511570.USD","BMED","LU2112291526.USD","LU1585245621.USD","LU0320765992.SGD","SG9999015986.USD","BBH","BK4532","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036059","title":"Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036059","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036059?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:55","pubTimestamp":1787867719,"startTime":"0","endTime":"0","summary":"Gilead (GILD) Sciences announced that the FDA approved Bixlenvo – bictegravir 75 mg/lenacapavir 50 mg -, the smallest once-daily single tablet regi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gileads-bixlenvo-approved-by-fda-for-virologically-suppressed-adults-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gileads-bixlenvo-approved-by-fda-for-virologically-suppressed-adults-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GILD","BK4566","LU0965509283.SGD","LU0109394709.USD","BK4532","BIB","LU1037948897.HKD","LU2357627491.SGD","BMED","LU1839511570.USD","LU1061106388.HKD","LU1934455194.USD","LU0889565916.HKD","TMED","LU1934455863.HKD","LABU","BBH","LU0823416689.USD","IBBQ","LU1066053197.SGD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU1674673428.USD","MEDI","LU1057294990.SGD","LU0234570918.USD","BK4588","SG9999015945.SGD","BK4583","BK4585","LU2324357040.USD","LU1674673691.USD","SG9999015952.SGD","LU0965509101.SGD","BK4139","TBXU","LU1066051498.USD","BK4568","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0859254822.USD","LU0861579265.USD","LU0122379950.USD","LU0058720904.USD","LU1023059063.AUD","SG9999015986.USD","IBB","LU1585245621.USD","LU2087621335.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036301","title":"US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036301","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036301?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867441,"startTime":"0","endTime":"0","summary":"US FDA approves Gilead's once-daily combination pill for HIV treatmentAug 27 -The U.S. Food and Drug Administration has approved Gilead Sciences'GILD.Oonce daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the company said on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O24M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","SG9999015945.SGD","LU0965509010.AUD","LU0114720955.EUR","LU2468319806.SGD","LU1934455277.USD","LU0889565916.HKD","BK4578","BK4588","LU0122379950.USD","IE00B19Z3581.USD","LU1023059063.AUD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0289739699.SGD","LU1934455863.HKD","BIB","IBBQ","LU0234570918.USD","LU1674673428.USD","LU2324357040.USD","MEDI","TBXU","LU1066051498.USD","LU1037948897.HKD","TMED","LU1061106388.HKD","LU1778281490.HKD","LU2357627491.SGD","BK4139","LU0861579265.USD","BBH","BK4585","LU1057294990.SGD","LU1585245621.USD","SG9999015952.SGD","GILD","BMED","BK4566","LU0882574055.USD","IE00B19Z3B42.SGD","IBB","LU0965508806.USD","LU1839511570.USD","BK4583","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0965509101.SGD","LU1037948541.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036807","title":"U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036807?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:47","pubTimestamp":1787867220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA7M9KZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1778281490.HKD","GILD","LU0882574055.USD","BK4588","LU1934455194.USD","BK4566","BK4583","LU1934455277.USD","LU1934455863.HKD","TMED","LU1061106388.HKD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU2089984988.USD","SG9999015978.USD","BK4550","LU1066053197.SGD","LU2468319806.SGD","LU1066051498.USD","BK4578","LU2112291526.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU1571399168.USD","IBBQ","LU0289739699.SGD","LU1057294990.SGD","MEDI","LU0234570918.USD","LU0861579265.USD","TBXU","IE00B3T34201.USD","LU2087621335.USD","BK4568","LU0965509283.SGD","BK4585","LU0965509010.AUD","LU1037948897.HKD","IBB","BMED","LU1430594728.SGD","IE00B19Z3B42.SGD","LU1839511570.USD","LU0889565916.HKD","BK4532","BBH","LU0823416689.USD","IE00BKVL7J92.USD","BIB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033626","title":"Moderna Inc. Stock Slips 4.6%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:34","pubTimestamp":1787862840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slid 4.6% to $142.77 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.6% to 26,541.35 and the Dow Jones Industrial Average rising 0.2% to 53,569.44.This was the stock's second consecutive day of losses.Moderna Inc. closed 19.2% short of its 52-week high of $176.66, which the company reached on August 19th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.6% to $265.77, Pfizer Inc. fell 1.0% to $28.02, and Gilead Sciences Inc. rose 0.52% to $148.86.Trading volume totaled 24.9 million, compared to the 50-day average of 16.4 million.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1037948541.HKD","LU2324357040.USD","IDNA","LU0861579265.USD","SG9999015945.SGD","LU0058720904.USD","GNOM","IE00BKVL7J92.USD","BIB","BK4583","BK4550","LU2357627491.SGD","BK4568","BK4139","LU0114720955.EUR","LU1934455277.USD","LU1934455194.USD","TBXU","MEDI","LU2468319806.SGD","GILD","LU0109394709.USD","LU1674673691.USD","IE00B7SZLL34.SGD","LU1674673428.USD","LU0889565916.HKD","SG9999015952.SGD","BK4534","BK4588","LU0320765992.SGD","LU0965508806.USD","IBBQ","BK4551","LU1061106388.HKD","LU1066053197.SGD","MRNY","BBH","LU0965509010.AUD","MRNA","IE00B19Z3581.USD","BK4533","MRNX","BMED","SG9999015986.USD","LU0965509283.SGD","WDNA","LGHT","LU1571399168.USD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084187","title":"Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084187","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084187?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848308,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-La...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","LU2468319806.SGD","BK4139","LU2242652126.USD","IE0009355771.USD","PBE","IE00B2B36J28.USD","AMGN","LU1983299246.USD","BK4588","LU0109394709.USD","LU0889565916.HKD","LU1061106388.HKD","BK4566","SG9999001440.SGD","LU2242646821.SGD","PJP","LU0289739699.SGD","TBXU","IBBQ","LU0320765992.SGD","BK4533","BBC","BBH","LU0122379950.USD","LU2089984988.USD","BK4534","IE00B4R5TH58.HKD","LU0868494617.USD","LU0058720904.USD","BK4599","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1571399168.USD","LU2112291526.USD","BK4581","LU1023059063.AUD","BK4585","IBB","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008458","title":"Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008458","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662008458?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:21","pubTimestamp":1787847665,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.Management emphasized that the label ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","BBH","IE00B4R5TH58.HKD","RVMD","CANC","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4139","IDNA","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0002141913.USD","IE0009354923.USD","PTH","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662813780","title":"Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662813780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662813780?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:20","pubTimestamp":1787844046,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and Amgen (AMGN). Verrica Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBBQ","IE00BJT1NW94.SGD","LU1057294990.SGD","LU2468319806.SGD","LABU","AMGN","XLV","LU2089984988.USD","IBB","LU0109394709.USD","BIB","HCSG","BBH","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0122379950.USD","LU2112291526.USD","LU0058720904.USD","LU0868494617.USD","LU1571399168.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4137","PBE","LU0029874061.USD","LU0128526141.USD","BK4581","BK4007","VRCA","TBXU","IE0009355771.USD","IE00B4R5TH58.HKD","BK4599","LU0889565916.HKD","BK4534","BK4139","XBI","LU2242652126.USD","BK4533","PJP","IE0002141913.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU1983299246.USD","LU0289739699.SGD","BK4585","SG9999001440.SGD","BK4566","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","PJP","LU0109394709.USD","IBBQ","02142","LU1061106388.HKD","LU1983299246.USD","BK1161","BK4585","BIB","BK4566","LU0289739699.SGD","BK4588","IE00B2B36J28.USD","LU0058720904.USD","LU1023059063.AUD","AMGN","IE0002141913.USD","PBE","SG9999001440.SGD","IE00BFTCPJ56.SGD","BK4139","IE00BJJMRZ35.SGD","BK4533","LU2242652126.USD","BK4581","BK1574","LU2468319806.SGD","LU0320765992.SGD","BK4599","LU0122379950.USD","LU1571399168.USD","IE0009355771.USD","IBB","LU1057294990.SGD","BBH","TBXU","LU2112291526.USD","BK1583","BK4534","LU0889565916.HKD","LU0868494617.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704855","title":"Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704855","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662704855?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:35","pubTimestamp":1787830554,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era** Revolution Medicines'RVMD.Ogroundbreakingpancreatic cancer drug, Rasonque, received the U.S. FDA approval on W","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0009354923.USD","IE00BJT1NW94.SGD","IE0009355771.USD","RVMD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00B2B36J28.USD","PTH","IDNA","BBH","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4139","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662013447","title":"Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662013447","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662013447?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:15","pubTimestamp":1787829352,"startTime":"0","endTime":"0","summary":"Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","BBH","LU2242652126.USD","BK4588","LU0868494617.USD","LU2237443622.USD","LU0432979614.USD","BK4139","AMGN","IBBQ","LU1829250122.USD","BK4581","AZN","LU2468319806.SGD","BK4534","LU2417539215.USD","BK4007","IE00B3T34201.USD","LU2237443978.SGD","LU0128525929.USD","LU2242646821.SGD","BK4568","IE00B4R5TH58.HKD","LU1057294990.SGD","LU2237443382.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU2237443465.HKD","BIB","BK4533","TBXU","LU0122379950.USD","LU2462157665.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","PBE","PJP","LU0289739699.SGD","LU2456880835.USD","IE0009355771.USD","LU2236285917.USD","LU1023059063.AUD","AZNH","LU0708994859.HKD","LU1267930573.SGD","LU2089984988.USD","BK4566","BK4585","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706801","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706801?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Immuneering (IMRX) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BBH","XBI","IDNA","CANC","IE0009355771.USD","BK4139","XLV","IE0002141913.USD","LU0029874061.USD","IMRX","LU0889565916.HKD","BK4563","IE0009354923.USD","BK4539","LU0109394709.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4588","LU0320765992.SGD","BK4585","RVMD","IE00BFTCPJ56.SGD","BK4137","LU0128526141.USD","BK4581","IE00BJT1NW94.SGD","LABU","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","LU0395794307.EUR","BBH","LU0463099449.HKD","IBB","IBBQ","IE0004445239.USD","LU1934455277.USD","LU2237443382.USD","LU2237443978.SGD","LU2097828714.EUR","XLV","MEDX","LU1037948897.HKD","RXL","IE00BVYPNV92.GBP","02126","LU0868494617.USD","LU1934455863.HKD","IE000SO60NU8.SGD","IYH","IE00BN8TJ469.HKD","REGN","TRUH","FHLC","PJP","LU0859254822.USD","FTXH","LU1188198961.HKD","LU0310799852.SGD","CMI","AGNG","PPH","TBXU","LU0949170772.SGD","BK1574","GLAM","LU0943347566.SGD","VHT","688331","KURE","LU2362541513.USD","LU0708994859.HKD","MADE","LU1244550577.SGD","03692","01801","IXJ","JDOC","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708397","title":"JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708397","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708397?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:58","pubTimestamp":1787824692,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics FY26 H1 IFRS loss narrows 81.14% to RMB 50.4 million; revenue rises 4.7% to RMB 111.4 millionJW Cayman Therapeutics posted IFRS revenue of RMB 111.4 million, up 4.7% year over y","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8Yh1j4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","LU0053666078.USD","BK1583","LU0058720904.USD","LU2362540622.SGD","BK4588","LU0823416689.USD","LU2106854487.HKD","LU0320765992.SGD","LU0289739699.SGD","REGN","BK4139","LU2362541513.USD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","LU0823434583.USD","BBH","LU2237438978.USD","LU2089984988.USD","LU2468319806.SGD","LU0882574055.USD","LU1917777945.USD","BK4585","TBXU","IBBQ","LU0823434740.USD","LU2023250504.SGD","LU2362541273.HKD","IBB","LU1974910355.USD","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662877754","title":"Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662877754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662877754?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822113,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esop...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZN","BBH","LU0029864427.USD","LU1023059063.AUD","PJP","LU1983299246.USD","BK4599","IBB","LU1267930573.SGD","LU2456880835.USD","PBE","LU2237443465.HKD","BK4533","LU0128525929.USD","BK4585","AMGN","LU1829250122.USD","BIB","LU0889565916.HKD","IE00BJT1NW94.SGD","LU2417539215.USD","LU1061106388.HKD","TBXU","IE0002141913.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B3T34201.USD","LU2236285917.USD","LU2237443895.HKD","LU2237443978.SGD","BK4588","BK4568","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU2112291526.USD","LU2242646821.SGD","IBBQ","BK4007","LU0122379950.USD","AZNH","LU0289739699.SGD","BK4581","LU0432979614.USD","LU0058720904.USD","IE00B2B36J28.USD","LU2468319806.SGD","IE0009355771.USD","LU1571399168.USD","LU0868494617.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771175","title":"AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771175?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:24","pubTimestamp":1787819085,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Amgen  said Thursday their drug Tezspire met the primary endpoints of a Phase 3 trial treating eosinophilic esophagitis, a chronic inflammatory esophagus disorder.The medication met both primary endpoints by reducing tissue inflammation and easing swallowing difficulties at week 24 compared to a placebo, the companies said.The disease and symptom improvements were maintained through week 52 for both tested doses, they said.The companies also said the safety profile of the treatment during the study remained consistent with its previously approved uses.Shares of Amgen were down by over 1% in Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TBXU","AZNH","IE00B4R5TH58.HKD","BK4534","LU2462157665.USD","LU2237443622.USD","LU2242652126.USD","LU0058720904.USD","LU0889565916.HKD","BBH","LU2242646821.SGD","BK4533","PJP","LU0708994859.HKD","BK4585","LU2089984988.USD","LU2237443465.HKD","LU1057294990.SGD","LU1061106388.HKD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","LU0128525929.USD","LU1267930573.SGD","BK4566","IE00BJT1NW94.SGD","LU2456880835.USD","IE00BFTCPJ56.SGD","LU0432979614.USD","LU1829250122.USD","BK4599","LU0029864427.USD","LU0310800379.SGD","AMGN","BIB","BK4581","IBBQ","AZN","IBB","LU0109394709.USD","LU2237443382.USD","LU0868494617.USD","LU1571399168.USD","IE00B2B36J28.USD","PBE","BK4007","LU2237443549.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775710","title":"Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775710?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:55","pubTimestamp":1787813720,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Corp. ( ($JP:5290) ). Vertex Corporation has been selected as a constituent of the JPX-Nikkei Mid and Small Ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRTX","IE00B2B36J28.USD","LU2468319806.SGD","IE00BZ9MQY76.HKD","LU2462157665.USD","VERX","BK4567","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","IBB","IBBQ","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4533","LU1585245621.USD","PBE","BIB","IE0002141913.USD","IE00B19Z3581.USD","LU2089984988.USD","IE00B19Z9P08.USD","IE00BJT1NW94.SGD","LU1069344957.HKD","LU1559883803.SGD","LU1815336091.USD","LU0566484027.USD","JPX","BK4532","BBH","SG9999013999.USD","LU0432979614.USD","TBXU","IE0002270589.USD","LU1093756168.USD","LU1430594728.SGD","BK4023","LU0079474960.USD","SG9999001176.USD","LU2417539215.USD","SGXZ57979304.SGD","LU2456880835.USD","LU0234570918.USD","LU0823416689.USD","LU1778281490.HKD","BK4585","IDNA","LU0109394709.USD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}